$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

$qlgn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223017315 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$1.607M	$722.0K
YoY Change	122.59%	-62.0%
Cost Of Revenue	$1.265M	$828.9K
YoY Change	52.6%	-30.93%
Gross Profit	$342.3K	-$106.8K
YoY Change	-420.48%	-115.26%
Gross Profit Margin	21.3%	-14.79%
Selling, General & Admin	$1.914M	$3.037M
YoY Change	-36.99%	0.9%
% of Gross Profit	558.96%
Research & Development	$2.122M	$1.865M
YoY Change	13.77%	-46.72%
% of Gross Profit	619.72%
Depreciation & Amortization	$58.67K	$29.75K
YoY Change	97.2%	-0.83%
% of Gross Profit	17.14%
Operating Expenses	$5.300M	$4.902M
YoY Change	8.12%	-24.7%
Operating Profit	-$3.693M	-$5.009M
YoY Change	-26.27%	-13.79%
Interest Expense	-$544.2K	$6.310K
YoY Change	-8725.04%	-99.71%
% of Operating Profit
Other Income/Expense, Net	-$578.3K	$160.0K
YoY Change	-461.42%
Pretax Income	-$4.271M	-$4.319M
YoY Change	-1.11%	17.69%
Income Tax	-$163.8K	$740.00
% Of Pretax Income
Net Earnings	-$3.846M	-$4.320M
YoY Change	-10.96%	-17.6%
Net Earnings / Revenue	-239.32%	-598.28%
Basic Earnings Per Share	-$0.78	-$1.22
Diluted Earnings Per Share	-$0.78	-$122.4K
COMMON SHARES
Basic Shares Outstanding	4.959M shares	3.529M shares
Diluted Shares Outstanding	4.959M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.363M	$13.61M
YoY Change	-67.95%	-37.99%
Cash & Equivalents	$4.368M	$13.61M
Short-Term Investments
Other Short-Term Assets	$12.16K	$1.098M
YoY Change	-98.89%	-10.01%
Inventory	$1.481M	$1.401M
Prepaid Expenses
Receivables	$411.1K	$594.3K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$7.538M	$16.70M
YoY Change	-54.87%	-32.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$522.4K	$1.822M
YoY Change	-71.32%	198.61%
Goodwill	$625.6K
YoY Change
Intangibles	$5.839M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.33K	$18.33K
YoY Change	0.02%	-8.35%
Total Long-Term Assets	$8.376M	$2.005M
YoY Change	317.83%	144.47%
TOTAL ASSETS
Total Short-Term Assets	$7.538M	$16.70M
Total Long-Term Assets	$8.376M	$2.005M
Total Assets	$15.91M	$18.71M
YoY Change	-14.94%	-27.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$899.9K	$997.4K
YoY Change	-9.77%	103.55%
Accrued Expenses	$1.894M	$1.423M
YoY Change	33.12%	-31.28%
Deferred Revenue
YoY Change
Short-Term Debt	$959.0K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.244M	$3.626M
YoY Change	127.39%	-60.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.277M	$1.566M
YoY Change	-18.47%	421.97%
Total Long-Term Liabilities	$1.277M	$1.566M
YoY Change	-18.47%	421.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.244M	$3.626M
Total Long-Term Liabilities	$1.277M	$1.566M
Total Liabilities	$9.714M	$5.192M
YoY Change	87.1%	-45.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.2M
YoY Change
Common Stock	$42.95K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.869M	$13.52M
YoY Change
Total Liabilities & Shareholders Equity	$15.91M	$18.71M
YoY Change	-14.94%	-27.32%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.846M	-$4.320M
YoY Change	-10.96%	-17.6%
Depreciation, Depletion And Amortization	$58.67K	$29.75K
YoY Change	97.2%	-0.83%
Cash From Operating Activities	-$2.600M	-$3.882M
YoY Change	-33.02%	86.62%
INVESTING ACTIVITIES
Capital Expenditures	$198.0K	-$49.63K
YoY Change	-498.97%	-29.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$198.0K	-$49.63K
YoY Change	298.97%	-29.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.860K
YoY Change		-96.78%
NET CHANGE
Cash From Operating Activities	-$2.600M	-3.882M
Cash From Investing Activities	-$198.0K	-49.63K
Cash From Financing Activities		3.860K
Net Change In Cash	-$2.832M	-3.927M
YoY Change	-27.89%	93.47%
FREE CASH FLOW
Cash From Operating Activities	-$2.600M	-$3.882M
Capital Expenditures	$198.0K	-$49.63K
Free Cash Flow	-$2.798M	-$3.832M
YoY Change	-26.98%	90.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001460702
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal		usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2022Q1	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt		usd
CY2022Q1	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt		usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q1	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability		usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease		usd
CY2023Q1	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
CY2022Q1	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock		usd
CY2023Q1	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease		usd
CY2023Q1	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
CY2023Q1	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2022Q1	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum		pure
CY2023Q1	us-gaap	Share Price SharePrice
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Qualigen Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37428
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3474527
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2042 Corte Del Nogal
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92011
CY2023Q1	dei	City Area Code CityAreaCode	(760)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	918-9165
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	QLGN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5052463	shares
CY2023Q1	us-gaap	Cash Cash	4362757	usd
CY2022Q4	us-gaap	Cash Cash	7034434	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	411104	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1480755	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1283358	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	7537974	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10820538	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5586	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5690	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1364901	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1422538	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522408	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5839330	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2023Q1	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2023Q1	us-gaap	Assets Assets	15914135	usd
CY2022Q4	us-gaap	Assets Assets	19083491	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	899948	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	857311	usd
CY2023Q1	QLGN	Accrued Vacation AccruedVacation	353557	usd
CY2022Q4	QLGN	Accrued Vacation AccruedVacation	467948	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1893733	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1511856	usd
CY2023Q1	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability	634330	usd
CY2022Q4	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability	780682	usd
CY2023Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	112902	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	116161	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	248809	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240645	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	958952	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	950722	usd
CY2023Q1	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	400800	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	788100	usd
CY2023Q1	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2183174	usd
CY2022Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2834547	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	558238	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	60197	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8244442	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8608170	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1236024	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1301919	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	40712	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49056	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	192587	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	357757	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9713766	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10316902	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5052463	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5052463	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4210737	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4210737	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	42952	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-261028	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3846221	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4319787	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4959122	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42110	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	111887447	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110528050	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	170444	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50721	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107231393	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103385172	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4869450	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7235709	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	1330919	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1530881	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6200369	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15914135	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19083491	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1607170	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	722029	usd
CY2023Q1	QLGN	Cost Of Product Sales CostOfProductSales	1264828	usd
CY2022Q1	QLGN	Cost Of Product Sales CostOfProductSales	828848	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1714434	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2898751	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2121551	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1864745	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	199114	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	138323	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5299927	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5730667	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3692757	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5008638	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1038673	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	683242	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-544236	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6309	usd
CY2023Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1077287	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4881	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36	usd
CY2023Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-300	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-578269	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	689587	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4271026	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4319051	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163777	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	736	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	111184	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3529405	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	119723	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3987526	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4319787	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-261028	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3726498	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4319787	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1112582	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	252226	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	176220	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6200369	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022Q1	QLGN	Stock Issued Upon Cash Exercise Of Warrants StockIssuedUponCashExerciseOfWarrants	4716	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1267166	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13516829	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	58667	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29749	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	57636	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	54495	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-120790	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-88129	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-1808	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	4074	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	252226	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1267166	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1038673	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-683242	usd
CY2023Q1	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt	-1077287	usd
CY2023Q1	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt	-533336	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-300	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-246645	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-316142	usd
CY2023Q1	QLGN	Increase Decrease In Inventory And Equipment Held For Leases IncreaseDecreaseInInventoryAndEquipmentHeldForLeases	-71379	usd
CY2022Q1	QLGN	Increase Decrease In Inventory And Equipment Held For Leases IncreaseDecreaseInInventoryAndEquipmentHeldForLeases	348908	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-377761	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-282074	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	43137	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	283431	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-450526	usd
CY2023Q1	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability	-132874	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-57731	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36297	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11603	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19606	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-165170	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2634093	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3881611	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	198009	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49625	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-198009	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49625	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3858	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3858	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2832100	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3927378	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160320	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7040124	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17538272	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4368343	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13610894	usd
CY2023Q1	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease	35971	usd
CY2022Q1	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
CY2023Q1	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock	1112582	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	These warrants were subsequently exercised on September 13, 2022
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zlThIhpBUdWi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zlFL5BjCayHl">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4239000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	478176	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	726449	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	67072	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187862	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	411104	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
CY2023Q1	QLGN	Allowances For Sales Return AllowancesForSalesReturn	35000	usd
CY2022Q1	QLGN	Allowances For Sales Return AllowancesForSalesReturn	43000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q1	us-gaap	Product Warranty Expense ProductWarrantyExpense	41000	usd
CY2022Q1	us-gaap	Product Warranty Expense ProductWarrantyExpense	53000	usd
CY2023Q1	us-gaap	Cash Cash	4400000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2600000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3900000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8800000	usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000.0	usd
CY2022	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company with a face value equal to the amount paid by the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all of the assets of NanoSynex; or iii) the initial public offering of NanoSynex
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	7048	shares
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	75336	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	120942	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Research And Development Expense BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense	5700000	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	4588	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses And Other Payables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables	-291093	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Research And Development Grant Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability	-1362264	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Short Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt	-941898	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	629379	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	-3882225	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1215169	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4789602	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	3574433	usd
CY2022	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	117775	usd
CY2022	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	106621	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	985396	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	949796	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	180324	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	200318	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	315035	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	436183	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1480755	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1142839	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1377323	usd
CY2023Q1	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	38503	usd
CY2022Q4	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	43820	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	89855	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	227451	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	12161	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12626	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1283358	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5231523	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5043533	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4634115	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4623446	usd
CY2023Q1	QLGN	Fixed Asset Impairments FixedAssetImpairments	-75000	usd
CY2022Q4	QLGN	Fixed Asset Impairments FixedAssetImpairments	-75000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522408	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2023Q1	us-gaap	Depreciation Depreciation	20000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	23000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	758608	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	752237	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	139330	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	145702	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5839330	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	15000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	14000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	14000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	65000	usd
CY2023Q1	QLGN	Accrued Compensation AccruedCompensation	42000	usd
CY2022Q4	QLGN	Accrued Compensation AccruedCompensation	70000	usd
CY2022Q4	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease	154433	usd
CY2023Q1	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	21562	usd
CY2022Q4	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	27531	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	6056	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4663	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	31124	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2829	usd
CY2023Q1	QLGN	Accrued License Fees AccruedLicenseFees	50013	usd
CY2022Q4	QLGN	Accrued License Fees AccruedLicenseFees	150130	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	277964	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	209303	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	328647	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238211	usd
CY2023Q1	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	722344	usd
CY2022Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	322987	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8772	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13158	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	150746	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137568	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	254505	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	181043	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1893733	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1511856	usd
CY2022Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	3622647	usd
CY2023Q1	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-1038673	usd
CY2023Q1	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	2583974	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1100000	usd
CY2023Q1	QLGN	Accrued Interest AccruedInterest	562000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	533000	usd
CY2023Q1	QLGN	Fair Value Adjustments Of Warrant FairValueAdjustmentsOfWarrant	2200000	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3846221	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4319787	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4959122	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3529405	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	4959122	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3529405	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4807327	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1468005	shares
CY2021Q4	us-gaap	Area Of Land AreaOfLand	22624	sqft
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	November 1, 2022 to November 30, 2027
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Payments For Rent PaymentsForRent	1950710	usd
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	QLGN	Tenant Improvement Allowance TenantImprovementAllowance	339360	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	276256	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	379392	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	390773	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	402497	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	379164	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1828082	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	343249	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1484833	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	116000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	114000	usd
CY2022Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	96558	usd
CY2023Q1	QLGN	License Cost LicenseCost	14000	usd
CY2022Q1	QLGN	License Cost LicenseCost	2000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4807327	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4807327	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.02	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Share Price SharePrice	1.05
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	252226	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1267166	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	60000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.20
CY2021	QLGN	Fair Value Of Issuance Cost FairValueOfIssuanceCost	300000	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	219101	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	40.70
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares

Files In Submission

Name	View Source	Status
qlgn-20230331_def.xml	Edgar Link	unprocessable
qlgn-20230331_pre.xml	Edgar Link	unprocessable
qlgn-20230331_lab.xml	Edgar Link	unprocessable
0001493152-23-017315-index-headers.html	Edgar Link	pending
0001493152-23-017315-index.html	Edgar Link	pending
0001493152-23-017315.txt	Edgar Link	pending
0001493152-23-017315-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qlgn-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qlgn-20230331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q1 Form 10-Q Financial Statement

#000149315223017315 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q1 Form 10-Q Financial Statement

#000149315223017315 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn